Non-Invasive Monitoring Systems Stock

Non-Invasive Monitoring Systems ROCE

The Return on Capital Employed (ROCE) of Non-Invasive Monitoring Systems (NIMU) as of Jul 15, 2026 is 16.90 %. In the previous year, Return on Capital Employed (ROCE) was 24.41 % — a change of -30.80% (lower).

ROCE

16.90 %

YoY

-30.80%

Last updated:

In 2026, Non-Invasive Monitoring Systems's return on capital employed (ROCE) was 16.90 %, a -30.80% increase from the 24.41 % ROCE in the previous year.

Access this data via the Eulerpool API

Non-Invasive Monitoring Systems Stock analysis

What does Non-Invasive Monitoring Systems do? Non-Invasive Monitoring Systems Inc (NIMS) has become a major player in the field of medical diagnostics and monitoring in recent years. The company was founded in 2002 and is headquartered in Miami, Florida. Its focus is on developing and marketing innovative non-invasive technologies that enable better patient care. NIMS' business model is based on the development and marketing of products that allow for fast and accurate diagnosis of various medical conditions. These technologies can be used in various clinical areas such as intensive care, oncology, cardiology, and neurology. The company's goal is to improve patient care by making diagnostics and monitoring faster, more accurate, and more effective. NIMS has several divisions that focus on different medical applications. One of these is the gastrointestinal division, which specializes in the diagnosis and monitoring of gastrointestinal disorders. NIMS offers innovative technologies such as magnetic resonance elastography (MRE-MRI), which allows for the measurement of tissue hardness without invasive procedures. This technology is particularly used in the early detection of cancer, as it enables the detection of tissue changes at an early stage. Another important division of NIMS is cardiovascular monitoring, which aims at the early detection and monitoring of heart diseases. The company offers various non-invasive technologies for this purpose, such as wearable devices for measuring blood pressure and heart rate, or ultrasound for measuring blood flow and vascular stiffness. These technologies are intended to improve the monitoring of patients with heart diseases and to detect complications at an early stage. NIMS also offers innovative diagnostic tools for the early detection of cancer, such as the Cancer Screening Index (CSI). The CSI is a biomarker-based test that calculates the probability of developing certain types of cancer. Various factors such as family history, smoking, or age are taken into account in the calculation. The CSI aims to contribute to the early detection of cancer and thus enable better prognosis. In addition to these products, NIMS is also involved in clinical research. The company offers specialized services such as conducting clinical trials or providing expert opinions. These services are intended to promote the development of new non-invasive diagnostic and monitoring technologies and thus improve overall patient care. Overall, NIMS has become a leading company in the field of non-invasive medical diagnostics and monitoring. The company is constantly striving to advance the development of new innovative technologies to improve patient care and minimize the use of invasive procedures. With its various divisions and products, NIMS is able to cover various medical applications and thus appeal to a broad customer base. Non-Invasive Monitoring Systems is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Non-Invasive Monitoring Systems's Return on Capital Employed (ROCE)

Non-Invasive Monitoring Systems's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Non-Invasive Monitoring Systems's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Non-Invasive Monitoring Systems's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Non-Invasive Monitoring Systems’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Non-Invasive Monitoring Systems stock

Return on Capital Employed (ROCE) of Non-Invasive Monitoring Systems is 16.90 % in 2026.

Access this data via the Eulerpool API

Profitability — Non-Invasive Monitoring Systems

All Key Metrics — Non-Invasive Monitoring Systems